A Study of LY3305677 in Healthy Participants

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: LY3305677; Drug: Placebo

• Registration Number: NCT02972645
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to evaluate the safety of LY3305677 and any side effects that might be associated with it.

This study will also look at how much LY3305677 gets into the blood stream, how long it takes the body to remove it.

This study involves a single dose of LY3305677 administered by subcutaneous injection (SC).

Participation in this study is expected to last up to 16 weeks.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-11-21
• Study First Submitted QC: 2016-11-21
• Study First Posted: 2016-11-23
• Study Start: 2016-12-05
• Status Verified: 2017-07
• Primary Completion: 2017-07-14
• Study Completion: 2017-07-14
• Last Update Submitted: 2017-07-21
• Last Update Posted: 2017-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Overtly healthy as determined by medical history and physical examination
• Male participants: will agree to use a reliable method of birth control and will not donate sperm during the study and for at least 3 months following the last dose of the investigational product
• Female participants: women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
• First generation Japanese participants or non-Japanese participants
• Have a body weight of more than 50 kilograms (kg)

Read More

Exclusion Criteria

• Have participated within the last 3 months in a clinical trial involving an investigational product
• Have known allergies to glucagon-like peptide-1 (GLP-1) analogs, or any components of the formulation, or history of significant atopy
• Have an abnormality in the 12-lead electrocardiogram (ECG) at screening and/or Day -1
• Have undergone any form of bariatric surgery
• Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis
• Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase
• Show evidence of human immunodeficiency virus (HIV) or Hepatitis B or C
• Have used or intend to use medications that promote weight loss
• Have donated blood of more than 500 milliliter (mL) within the last month
• Currently smoke more than 10 cigarettes per day

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LY3305677	LY3305677	Single escalating doses of LY3305677 administered subcutaneously (SC)
Placebo	Placebo	Placebo administered SC

Primary Outcome Measures

Name	Time	Method
Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration	Baseline to Study Completion (approximately 16 weeks)

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3305677	Day 1 Pre-dose through Day 85
Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3305677	Day 1 Pre-dose through Day 85

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.; 🇬🇧 Leeds, United Kingdom